The slow-channel congenital myasthenic syndrome (SCCMS) is caused by g
ain of function mutations in subunits of the end-plate acetylcholine r
eceptor (AChR), The mutations prolong the opening episodes of the AChR
channel, leading to a depolarization block and an end-plate myopathy
Because levels of quinidine sulfate attainable in clinical practice sh
orten the opening episodes of genetically engineered mutant SCCMS rece
ptors in vitro, we tested the notion that the drug can be of benefit i
n SCCMS. We treated 6 SCCMS patients with quinidine sulfate in an open
-label trial, using objective clinical measures of muscle strength and
repetitive stimulation studies as end points. One patient became alle
rgic to quinidine after 7 days. The remaining patients tolerated the d
rug well and after 30 days of continuous therapy showed statistically
significant improvement in muscle strength and in decrement of the com
pound muscle action potential elicited by rapid rates of stimulation.